Citations

Clear

1446 citation(s) found for "Howard, F".

A framework for translating tauopathy therapeutics: Drug discovery to clinical trials
Feldman, Howard , Cummings, Jeffrey L., Boxer, Adam L., Staffaroni, Adam M. , Knopman, David S., Territo, Paul R. , Arnold, Steven E. , Boeve, Bradley F., Dacks, Penny A. , Diaz, Kristophe , Ewen, Colin, González, María Isabel , Harris, Glenn A., Hoffman, Beth J., Martinez, Terina N. , Nisenbaum, Laura K., Palma, Jose‐Alberto , Quintana, Melanie , Rabinovici, Gil D. , Rohrer, Jonathan D. , Rosen, Howard J., Troyer, Matthew D. , Kim, Doo Yeon , Tanzi, Rudolph E. , Zetterberg, Henrik, Ziogas, Nick, May, Patrick C. , Rommel, Amy, Feldman, Howard H , Palma, Jose-Alberto , Rohrer, Jonathan D , Rabinovici, Gil D , Dacks, Penny , Boxer, Adam L. , Knopman, David S. , Rizzo, Stacey J. Sukoff , Ballard, Clive , Beher, Dirk , Boeve, Bradley F. , Fiske, Brian , McDade, Eric , Zetterberg, Henrik

Mayo Clinic

Alzheimer's & Dementia | September 24, 2024 | Volume: 20 | Issue: 11 | Pages: 8129-8152

10.1002/alz.14250 | PMID 39316411 Get It

AbstractThe tauopathies are defined by pathological tau protein aggregates within a spectrum of clinically heterogeneous neurodegenerative diseases. The primary tauopathies meet the definition of rare diseases in the United States. There is no approved treatment for primary tauopathies. In this context, designing the most efficient development programs to translate promising targets and treatments from preclinical studies to early‐phase clinical trials is vital. In September 2022, the Rainwater Charitable Foundation convened an international expert workshop focused on the translation of tauopathy therapeutics through early‐phase trials. Our report on the workshop recommends a framework for principled drug development and a companion lexicon to facilitate communication focusing on reproducibility and achieving common elements. Topics include the selection of targets, drugs, biomarkers, participants, and study designs. The maturation of pharmacodynamic biomarkers to demonstrate target engagement and surrogate disease biomarkers is a crucial unmet need.Highlights Experts provided a framework to translate therapeutics (discovery to clinical trials). Experts focused on the “5 Rights” (target, drug, biomarker, participants, trial). Current research on frontotemporal degeneration, progressive supranuclear palsy, and corticobasal syndrome therapeutics includes 32 trials (37% on biologics) Tau therapeutics are being tested in Alzheimer's disease; primary tauopathies have a large unmet need.
Improved technical outcomes with converting thrombectomy techniques after failed first pass recanalization
Matsukawa, Hidetoshi , Matouk, Charles , Uchida, Kazutaka , Kasab, Sami Al , Sowlat, Mohammad‐Mahdi , Elawady, Sameh Samir , Maier, Ilko , Jabbour, Pascal , Kim, Joon‐Tae , Wolfe, Stacey Q , Rai, Ansaar , Starke, Robert M., Psychogios, Marios‐Nikos, Howard, B, Tanweer, Omar , Polifka, Adam , Crosa, Roberto , Park, Min S. , Brinjikji, Waleed , Williamson, Richard , Kan, Peter , Chowdhry, Shakeel , Ezzeldin, Mohamad , Spiotta, Alejandro M , Yoshimura, Shinichi , Al Kasab, Sami , Rai, Ansaar , Arthur, Adam Stephen , Cuellar-Saenz, Hugo H , Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Crosa, Roberto , Levitt, Michael R , Brinjikji, Waleed , Navia, Pedro , Kan, Peter , De Leacy, Reade , Ezzeldin, Mohamad , Spiotta, Alejandro M , Alawieh, Ali M , Matouk, Charles , Wolfe, Stacey Quintero , Matsukawa, Hidetoshi , Sowlat, Mohammad-Mahdi , Jabbour, Pascal , Samaniego, Edgar A , Cuellar, Hugo , Howard, Brian M., Romano, Daniele Giuseppe , Fragata, Isabel , Levitt, Michael R. , Moss, Mark, Navía, Pedro , Leacy, Reade De , Alawieh, Ali

Mayo Clinic

Journal of NeuroInterventional Surgery | September 20, 2024 | Volume: 17 | Issue: 12 | Pages: 1333-1339

10.1136/jnis-2024-022071 | PMID 39304195 Get It

Background A higher number of recanalization attempts reduces the efficacy of endovascular thrombectomy (EVT) for acute ischemic stroke secondary to large vessel occlusion (LVO). We assessed the impact of switching EVT techniques after a failed first pass on procedural and clinical outcomes. Methods This multicenter international study, conducted between January 2013 and December 2022, included patients undergoing EVT for anterior circulation LVO (internal carotid artery or M1 segments) with failed first pass recanalization. Propensity score matching identified a 1:1 matched cohort of patients in whom EVT technique was changed after a failed first pass and those with the same technique repeated. The primary outcome was successful recanalization at second attempt defined as Thrombolysis in Cerebral Ischemia (TICI) score of 2B or higher. Secondary outcomes were 90-day modified Rankin Score (mRS) and postprocedural hemorrhage. Results Among 2167 patients, converting to an alternative technique after a failed first pass was associated with higher odds of successful recanalization (adjusted OR (aOR)=1.5, p=0.041), and higher odds of mRS 0–2 at 90 days (aOR=1.6, p=0.005) without additional risk of symptomatic hemorrhage (p=0.379). Using a propensity score matched cohort of 490 patients, technique conversion at second attempt increased odds of successful recanalization at second attempt (aOR=1.32, p=0.006) and 90-day mRS 0–2 (aOR=1.38, p=0.008). Conclusions Early conversion to an alternative EVT technique after a failed first pass recanalization in patients with AIS is associated with better technical success and clinical outcomes.
Loss‐of‐Function Variants in CUL3 Cause a Syndromic Neurodevelopmental Disorder
Blackburn, Patrick R. , Herkert, Johanna C. , Rinne, Tuula , Thiffault, Isabelle, Rapp, Michele, Alders, Mariel, Maas, Saskia M. , Gérard, Bénédicte, Smol, Thomas , Vincent‐Delorme, Catherine , Isidor, Bertrand , Joset, Pascal , Husson, Thomas , Guerrot, Anne‐Marie , Bacino, Carlos A. , Macmurdo, Colleen, Thompson, Stephanie S., Faivre, Laurence , Deb, Wallid , Vignard, Virginie , Goldenberg, Alice, Lecoquierre, François , Zech, Michael , Necpál, Ján , Winkelmann, Juliane , Koprušáková, Monika Turčanová , Konstantopoulou, Vassiliki , Younce, John R. , Mighton, Chloe, Fung, Charlotte, Morel, Chantal F. , Barth, Magalie , Krapels, Ingrid P.C. , Schoot, Vyne van der , Bußmann, Cornelia, Wortmann, Saskia B. , Ravelli, Claudia , Keren, Boris , Ziegler, Alban , Hasadsri, Linda , Pichurin, Pavel N. , Klee, Eric W. , Grand, Katheryn , Sanchez‐Lara, Pedro A. , Krüger, Elke , Klinkhammer, Hannah , Tartaglia, Marco , Wang, Tianyun , Prokisch, Holger , Shinawi, Marwan , Brunet, Theresa , Tartaglia, Marco , Wang, Tianyun , Lecoquierre, Francois , Faivre, Laurence , Ebstein, Frédéric , Hsieh, Tzung‐Chien , Motta, Marialetizia , Radio, Francesca Clementina , Cogné, Benjamin , Vincent, Marie , Bachmann‐Gagescu, Ruxandra , Rauch, Anita , Ferrero, Giovanni Battista , Ciolfi, Andrea , Rosenfeld, Jill A. , Mau‐Them, Frédéric Tran , Agrawal, Pankaj B. , Madden, Jill A. , Goldenberg, Alice , Jech, Robert , Shinawi, Marwan , Lerner‐Ellis, Jordan P. , DiTroia, Stephanie P. , Bonneau, Dominique , Stegmann, Alexander P.A. , Mignot, Cyril , Zampino, Giuseppe , Mayr, Johannes A , Feichtinger, René G. , Courtin, Thomas , Bezieau, Stéphane , Krawitz, Peter Michael , Eichler, Evan E , Küry, Sébastien

Mayo Clinic

Annals of Neurology | September 20, 2024 | Volume: 97 | Issue: 1 | Pages: 76-89

10.1002/ana.27077 | PMID 39301775 Get It

ObjectiveDe novo variants in cullin‐3 ubiquitin ligase (CUL3) have been strongly associated with neurodevelopmental disorders (NDDs), but no large case series have been reported so far. Here, we aimed to collect sporadic cases carrying rare variants in CUL3, describe the genotype–phenotype correlation, and investigate the underlying pathogenic mechanism.MethodsGenetic data and detailed clinical records were collected via multicenter collaboration. Dysmorphic facial features were analyzed using GestaltMatcher. Variant effects on CUL3 protein stability were assessed using patient‐derived T‐cells.ResultsWe assembled a cohort of 37 individuals with heterozygous CUL3 variants presenting a syndromic NDD characterized by intellectual disability with or without autistic features. Of these, 35 have loss‐of‐function (LoF) and 2 have missense variants. CUL3 LoF variants in patients may affect protein stability leading to perturbations in protein homeostasis, as evidenced by decreased ubiquitin‐protein conjugates in vitro. Notably, we show that 4E‐BP1 (EIF4EBP1), a prominent substrate of CUL3, fails to be targeted for proteasomal degradation in patient‐derived cells.InterpretationOur study further refines the clinical and mutational spectrum of CUL3‐associated NDDs, expands the spectrum of cullin RING E3 ligase‐associated neuropsychiatric disorders, and suggests haploinsufficiency via LoF variants is the predominant pathogenic mechanism. ANN NEUROL 2025;97:76–89
Iltamiocel Autologous Cell Therapy for the Treatment of Female Stress Urinary Incontinence: A Double‐Blind, Randomized, Stratified, Placebo‐Controlled Trial
Kaufman, Melissa R. , Goldman, Howard B. , Chermansky, Christopher , Dmochowski, Roger R. , Peters, Kenneth M. , Quiroz, Lieschen H. , Bennett, Jason , Thomas, Sherry , Marguet, Charles G., Benson, Kevin , Wolter, Christopher , Katz, Daniel , Tarnay, Christopher M. , Antosh, Danielle D. , Heit, Michael , Rehme, Christian, Karram, Mickey M., Canestrari, Emanuele , Jankowski, Ron J. , Chermansky, Christopher J , Dmochowski, Roger , Lee, Una J , Wolter, Christopher E, Canestrari, Emanuele , Jankowski, Ron J , Chancellor, Michael B , KENNELLY, MICHAEL J. , Sokol, Eric R. , Katz, Daniel M., Snyder, Scott

Mayo Clinic

Neurourology and Urodynamics | September 16, 2024 | Volume: 43 | Issue: 8 | Pages: 2290-2299

10.1002/nau.25588 | PMID 39282854 Get It

ABSTRACTAimsThis study aimed to determine the efficacy and safety of iltamiocel investigational autologous muscle cell therapy in females with stress urinary incontinence (SUI).MethodsAdult females were randomized 2:1 to iltamiocel (150 × 106 cells) or placebo and stratified by severity and prior SUI surgery. The primary objective was efficacy based on the frequency of stress incontinence episodes (SIE) recorded in a 3‐day diary at 12 months posttreatment. After 12 months, placebo participants could elect to receive open‐label iltamiocel. Efficacy and safety analyses were performed using all patients as treated populations.ResultsThe study enrolled 311 patients, 297 were randomized to either iltamiocel (n = 199) or placebo (n = 98). Of the 295 participants that completed 12 months blinded follow‐up, the proportion achieving the primary endpoint of ≥ 50% SIE reduction was not statistically different between treatment groups (52% vs. 53.6%; p = 0.798). A significantly greater proportion of iltamiocel participants in the prior SUI surgery stratum group achieved ≥ 75% SIE reduction compared with placebo, (40% vs. 16%; p = 0.037). Treatment response was maintained at 24 months in 78.4% and 64.9% of iltamiocel participants who achieved ≥ 50% and ≥ 75% SIE reduction, respectively, at Month 12. Adverse events related to the treatment were reported in 19 (9.5%) iltamiocel participants and 6 (6.1%) placebo participants.ConclusionThe study did not meet its primary endpoint however, iltamiocel cell therapy is safe and may be ideally suited to female patients who have undergone prior surgery for SUI. Additional study in this group of patients with high unmet medical needs is warranted.Trial RegistrationClinicalTrials.gov identifier: NCT01893138; EudraCT number: 2014‐002919‐41.
Stevens‐Johnson syndrome and toxic epidermal necrolysis‐like eruptions in patients treated with immune checkpoint inhibitors: a systematic review
Akpala, Christeebella O. , Erfani, Yassaman J., Young, Jordan , Saeidi, Vahide , Chelf, Cynthia , Philips, Elizabeth J, Alavi, Afsáneh , Chelf, Cynthia J , Alavi, A , Akpala, Christeebella O , Todd, Austin W.

Mayo Clinic

International Journal of Dermatology | September 16, 2024 | Volume: 63 | Issue: 12 | Pages: No page available

10.1111/ijd.17479 | PMID 39279714 Get It

Abstract Background Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by targeting immune checkpoints such as PD‐1, PDL‐1, and CTLA‐4, but concerns about severe immune‐related adverse events persist. The scarcity of literature on dermatologic implications, especially severe reactions such as Stevens‐Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), highlights the urgent need for investigation. Objective Our systematic review aims to address the gap in relevant literature by extensively examining the epidemiologic risk factors and management of SJS/TEN‐like illnesses in ICI‐treated patients to provide insights for risk assessment and clinical care. Method s We identified 158 case reports that detailed the incidence of SJS/TEN in patients being treated with ICIs, examining demographic patterns, type of malignancy, clinical characteristics, and treatments linked to onset. We assessed mortality rates, risk elements, and the effectiveness of interventions to help guide clinical care. Results Analysis of 158 case reports revealed that SJS/TEN in ICI users is typically seen on average at the age of 63 and is more common in males. PD1 inhibitors such as nivolumab and pembrolizumab are often associated with various mucocutaneous patterns and significant risks with ICI use, especially TEN, which is linked to high morbidity and mortality rates. Limitations Our study notes limitations due to the inclusion of case reports or case series, such as potential publication and reporting biases, leading to skewed findings. Additionally, because of the heterogeneous reporting standards, the retrospective nature limits phenotypic precision, control for confounding variables, and data completeness. Conclusion Our study provides valuable insights into the epidemiology, clinical features, management strategies, and outcomes of ICI‐induced SJS/TEN, underscoring the importance of vigilant monitoring and personalized risk assessment in oncology practice. Continued research efforts are essential to optimize patient outcomes and enhance the safety profile of ICIs in cancer therapy.
The effect of intravenous thrombolysis in stroke patients with unsuccessful thrombectomy
Elawady, Sameh Samir , Kasem, Rahim Abo , Sowlat, Mohamed Mahdi, Nawabi, Noah, Venegas, Joshua M. , Isidor, Julio , Loulida, Hasna , Maier, Ilko , Kim, Joon-Tae , Wolfe, Stacey Q , Rai, Ansaar, Starke, Robert M. , Psychogios, Marios‐Nikos, Yoshimura, Shinichi , Alaraj, Ali , Ezzeldin, Mohamad , Tanweer, Omar , Polifka, Adam , Siddiqui, Fazeel , Crosa, Roberto , Park, Min S. , Brinjikji, Waleed , Moss, Mark, Dağlıoğlu, Ergün , Williamson, Richard , Kan, Peter, Chowdhry, Shakeel , Altschul, David , Spiotta, Alejandro M , Kasab, Sami Al , Venegas, Joshua M , Wolfe, Stacey Quintero , Yoshimura, Shinichi , Cuellar-Saenz, Hugo H , Alaraj, Ali , Ezzeldin, Mohamad , Fragata, Isabel , Grandhi, Ramesh , Matouk, Charles , Altschul, David J , Crosa, Roberto , Abo Kasem, Rahim , Matsukawa, Hidetoshi , Cunningham, Conor M. , Orscelik, Atakan , Jabbour, Pascal , Rai, Ansaar , Samaniego, Edgar A , Goyal, Nitin , Cuellar, Hugo , Howard, Brian M , Alawieh, Ali , Romano, Daniele Giuseppe , Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Grandhi, Ramesh , Matouk, Charles , Levitt, Michael R. , Navía, Pedro , Leacy, Reade De

Mayo Clinic

Interventional Neuroradiology | September 13, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199241279009 | PMID 39262342 Get It

Background The benefit of intravenous thrombolysis (IVT) is well established. We aim to study the benefits of IVT in acute ischemic stroke (AIS) patients with large vessel occlusion (LVO) who underwent unsuccessful mechanical thrombectomy (MT). Methods We included AIS patients who underwent MT for anterior circulation LVO with failed recanalization (modified treatment in cerebral ischemia [mTICI] score ≤ 2A). Patients who received IVT prior to MT were compared to those who received MT alone. Propensity score matching using demographic, clinical, radiographic and procedural variables was used to match patients with and without IVT. The primary outcome was favorable 90-day good functional outcome (defined as modified Rankin scale of 0–2), and secondary outcomes included intracranial hemorrhage (ICH), symptomatic ICH (sICH), and 90-day mortality. Results Totally, 610 AIS patients with unsuccessful MT were included. After propensity matching, 219 patients were identified in each group. Median age was 70 years and 73 years in the IVT + MT and MT alone groups, respectively. In the IVT + MT group, final mTICI scores of 0, 1, and 2A were achieved in 92 (42.0%), 33 (15.1%), and 94 (42.9%) patients, respectively, versus 76 (34.7%), 29 (13.2%), and 114 (52.1%) in the MT alone group. The IVT + MT group had greater odds of 90-day good functional outcome (adjusted odds ratio 2.54, 95% confidence interval 1.53–4.32). There were no significant differences in secondary outcomes. Conclusions IVT is associated with improved functional outcomes in AIS patients with LVO despite unsuccessful MT.
Better cardiovascular health is associated with slowed clinical progression in autosomal dominant frontotemporal lobar degeneration variant carriers
VandeBunte, Anna M. , Staffaroni, Adam M. , Yaffe, Kristine , Ramos, Eliana Marisa , Rascovsky, Katya, Wong, Bonnie , Domoto‐Reilly, Kimiko , Snyder, Allison , Pressman, Peter , Mendez, Mario F. , Fields, Julie A. , Darby, Ryan, Masdeu, Joseph C. , Pasqual, Maria Belen, Ghoshal, Nupur , Mackenzie, Ian R. , Heuer, Hilary W. , Kramer, Joel H. , Boxer, Adam L. , Forsberg, Leah K. , Rosen, Howard J., Casaletto, Kaitlin B. , Domoto-Reilly, Kimiko , Snyder, Allison , Lee, Hyun Woo , Paolillo, Emily W. , Hsiung, Ging‐Yuek Robin , Saloner, Rowan , Tartaglia, Maria Carmela , Knopman, David S. , Bozoki, Andrea C , Litvan, Irene , Galasko, Douglas , Masdeu, Joseph C , Honig, Lawrence S. , Appleby, Brian S. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | September 6, 2024 | Volume: 20 | Issue: 10 | Pages: 6820-6833

10.1002/alz.14172 | PMID 39240048 Get It

AbstractINTRODUCTIONCardiovascular health is important for brain aging, yet its role in the clinical manifestation of autosomal dominant or atypical forms of dementia has not been fully elucidated. We examined relationships between Life's Simple 7 (LS7) and clinical trajectories in individuals with autosomal dominant frontotemporal lobar degeneration (FTLD).METHODSTwo hundred forty‐seven adults carrying FTLD pathogenic genetic variants (53% asymptomatic) and 189 non‐carrier controls completed baseline LS7, and longitudinal neuroimaging and neuropsychological testing.RESULTSAmong variant carriers, higher baseline LS7 is associated with slower accumulation of frontal white matter hyperintensities (WMHs), as well as slower memory and language declines. Higher baseline LS7 associated with larger baseline frontotemporal volume, but not frontotemporal volume trajectories.DISCUSSIONBetter baseline cardiovascular health related to slower cognitive decline and accumulation of frontal WMHs in autosomal dominant FTLD. Optimizing cardiovascular health may be an important modifiable approach to bolster cognitive health and brain integrity in FTLD.Highlights Better cardiovascular health associates with slower cognitive decline in frontotemporal lobar degeneration (FTLD). Lifestyle relates to the accumulation of frontal white matter hyperintensities in FTLD. More optimal cardiovascular health associates with greater baseline frontotemporal lobe volume. Optimized cardiovascular health relates to more favorable outcomes in genetic dementia.
Repetitive Head Impacts and Perivascular Space Volume in Former American Football Players
Jung, Leonard , Wiegand, Tim L. T. , Tuz‐Zahra, Fatima , Iliff, Jeffrey J. , Piantino, Juan , Arciniega, Hector , Kim, Cara L., Pankatz, Lara, Lin, Alexander , Alosco, Michael L. , Daneshvar, Daniel H. , Pasternak, Ofer , Coleman, Michael J. , Bernick, Charles , Balcer, Laura J. , Reiman, Eric M. , Shenton, Martha E., Protas, Hillary , Boker, Conni, Kowall, Neil W. , Otis, James , Weller, Jason , Simkin, Irene, Andino, Alondra, Diamond, Courtney , Fagle, Tessa, Haller, Olivia, Hung, Tennyson, Gullotti, Nicole, Mariani, Megan, Mayville, Brian, McLaughlin, Kathleen , Nanna, Mary, Platt, Taylor, Pulukuri, Sury, Rica, Fiona, Sestak, Madison, Annis, Douglas S. , Dixon, Dianne B., Finney, Carolyn, Gallagher, Kerrin, Hartlage, Kaitlin , Martin, Brett, Palmisano, Joseph , Pine, Brittany, Fitzsimmons, Jennifer, Breedlove, Katherine M. , Coello, Eduardo , Liao, Hujiun, Rizzoni, Elizabeth, Schultz, Vivian , Silva, Annelise, Vessey, Brynn, Banks, Sarah J. , Ritter, Aaron, Sabbagh, Marwan N. , Cruz, Raelynn de la, Durant, Jan, Golceker, Moragn, Harmon, Nicolette, Kaylegian, Kaeson, Long, Rachelle, Nance, Christin, Sandoval, Priscilla, Serrano, Andrew, Falk, Bryce W., Duffy, Amy, Howard, Marci, Montague, Michelle , Osgood, Thomas, Babcock, Debra, Kirov, Ivian, Marmar, Charles R. , Hasanaj, Lisene, Serrano, Liliana , Al-Kharafi, Alhassan, George, Allan , Martin, Sammie, Runge, William, Peskind, Elaine R. , Colasurdo, Elizabeth A. , Marcus, Daniel S. , Gurney, Jenny , Johnson, Keith A. , Greenwald, Richard M., Shenton, Martha E. , Daneshvar, Daniel H , Shenton, Martha E , Tripodis, Yorghos , Bouix, Sylvain , Mez, Jesse , Sepehrband, Farshid , Rathi, Yogesh , Adler, Charles H. , Cummings, Jeffrey L. , Stern, Robert A. , Koerte, Inga K , Su, Yi , Chen, Kewei , Boker, Connie, Au, Rhoda , Cantu, Robert C. , Farrer, Lindsay A. , Helm, Robert H. , Mercier, Gustavo , Conneely, Shannon E. , Diamond, Courtney, Pulukuri, Surya Vamsi , McClean, Michael D , Annis, Douglas, Chaisson, Christine E. , Finney, Carolyn, Lü, Jun , Ojo, Emmanuel, Ramachandran, Janani , Bonke, Elena M. , Breedlove, Katherine , Miller, Jason Rafe , II, Robert W. Turner , Marek, Kenneth , Dodick, David W. , Geda, Yonas E. , Wethe, Jennifer V. , Falk, Bryce, Montague, Michelle, Barr, William , Goldberg, Judith D. , Wısnıewskı, Thomas , Lui, Yvonne W. , George, Allan, Riley, Edward P.

Mayo Clinic

JAMA Network Open | August 26, 2024 | Volume: 7 | Issue: 8 | Pages: e2428687

10.1001/jamanetworkopen.2024.28687 | PMID 39186275 Get It

ImportanceExposure to repetitive head impacts (RHI) is associated with increased risk for neurodegeneration. Accumulation of toxic proteins due to impaired brain clearance is suspected to play a role.ObjectiveTo investigate whether perivascular space (PVS) volume is associated with lifetime exposure to RHI in individuals at risk for RHI-associated neurodegeneration.Design, Setting, and ParticipantsThis cross-sectional study was part of the Diagnostics, Imaging, and Genetics Network for the Objective Study and Evaluation of Chronic Traumatic Encephalopathy (DIAGNOSE CTE) Research Project, a 7-year multicenter study consisting of 4 US study sites. Data were collected from September 2016 to February 2020 and analyses were performed between May 2021 and October 2023. After controlling for magnetic resonance image (MRI) and processing quality, former American football players and unexposed asymptomatic control participants were included in analyses.ExposurePrior exposure to RHI while participating in American football was estimated using the 3 cumulative head impact indices (CHII-G, linear acceleration; CHII-R, rotational acceleration; and CHII, number of head impacts).Main Outcomes and MeasuresIndividual PVS volume was calculated in the white matter of structural MRI. Cognitive impairment was based on neuropsychological assessment. Linear regression models were used to assess associations of PVS volume with neuropsychological assessments in former American football players. All analyses were adjusted for confounders associated with PVS volume.ResultsAnalyses included 224 participants (median [IQR] age, 57 [51-65] years), with 170 male former football players (114 former professional athletes, 56 former collegiate athletes) and 54 male unexposed control participants. Former football players had larger PVS volume compared with the unexposed group (mean difference, 0.28 [95% CI, 0.00-0.56]; P = .05). Within the football group, PVS volume was associated with higher CHII-R (β = 2.71 × 10−8 [95% CI, 0.50 × 10−8 to 4.93 × 10−8]; P = .03) and CHII-G (β = 2.24 × 10−6 [95% CI, 0.35 × 10−6 to 4.13 × 10−6]; P = .03). Larger PVS volume was also associated with worse performance on cognitive functioning in former American football players (β = −0.74 [95% CI, −1.35 to −0.13]; P = .04).Conclusions and RelevanceThese findings suggest that impaired perivascular brain clearance, as indicated by larger PVS volume, may contribute to the association observed between RHI exposure and neurodegeneration.